Could a lower dose of Clot-Buster be safer and just as effective for lung infections?
NCT ID NCT05766124
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study tests whether a lower dose (2.5 mg) of a clot-busting drug called tPA works as well as the standard dose (10 mg) for people with serious lung infections that aren't clearing up. About 30 adults will be randomly assigned to one of the two doses, given directly into the chest. The main goal is to see if the study plan is practical, while also checking safety and how well each dose clears the infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.